Navigation Links
Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
Date:9/28/2007

ehensive cancer centre in Europe. This relationship enables close daily contact between research scientists and those on the frontline in the fight against cancer - the clinicians, the carers and most importantly, the patients.

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the Company's expectations related to the Phase Ia/Ib U.K. combination REOLYSIN(R) and radiation clinical trial, and the Company's belief as to the potential of REOLYSIN(R) as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN(R) as a cancer treatment, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN(R), uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements.


'/>"/>
SOURCE Oncolytics Biotech Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. The state of global biotech: An Ernst & Young perspective
2. Olympics of biotechnology has international flavor
3. Biotech officials praise focus of new venture fund
4. Getting noticed in Genetown: Wisconsin biotech on display
5. Madison biotech NimbleGen files for IPO; one of states best-funded firms
6. Wisconsin biotech firm receives $107K NIH grant
7. Biotech executive books a career flight thats closer to home
8. Manufacturing partnership will move into biotech and biomedical spaces
9. Wisconsin wont get Georgia biotech without a fight
10. The 10 biggest events shaping biotech in 2006
11. Gala Biotech among companies sold for $3.3 billion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)NANJING, China, Dec. 2 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group,("Simcere" or the "Company") (NYSE: SCR ), a leading pharmaceutical company,specializing in the development, manufacturing, a
(Date:12/2/2009)SHANGHAI, Dec. 2 /PRNewswire-Asia/ -- The world is going through,extraordinary times; markets are in turmoil and uncertainty is part of many,businesses and industries. It turns out that the pharma ind
(Date:12/2/2009)HOBOKEN, N.J., Dec. 2 According to the National Institute of Health, 40 percent to 45 percent of Americans diagnosed with diabetes already have some stage of diabetic retinopathy. Diabetic retinopat
(Date:12/1/2009)INCLINE VILLAGE, Nev., Dec. 1 PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI ) today announced revenue guidance for the fourth quarter ended December 31, 2009 of approximately $57 million, as compared with
Breaking Biology Technology:Simcere Announces 105 Drugs Included in China's National Drug Reimbursement List 2Simcere Announces 105 Drugs Included in China's National Drug Reimbursement List 3Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 2Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 3Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 2Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 3Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 4PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million 2PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million 3
...Oct. 29 Ventaira Pharmaceuticals,announced today ...t leader,will acquire Ventaira,s assets and assist...ms of the acquisition were not disclosed. "We wil...s. In,addition, we will work closely with Battelle...yees," said Leslie Williams, President and CEO,of ...
..., Oct. 29 TorreyPines Therapeutics,Inc. (Nasdaq: ...dent and,Chief Executive Officer of TorreyPines, w...9th Annual Healthcare Conference in New York on Mo...t of Dr. Kurtz,s presentation will be available li...reypinestherapeutics.com . An archived version,of ...
..., Oct. 29 Immunosyn,Corporation (OTC Bulletin Boa...d Criner as the company,s Chief Financial and Acco... and Accounting Officer, Douglas A.,McCain, Jr., h... Board and,further retains his position as Corpora...logy and its resulting,biopharmaceutical product c...
Other Biology Technology:Ventaira Pharmaceuticals Announces Acquisition of Assets by Battelle 2Immunosyn Corporation Names G. David Criner as CFO 2
(Date:12/3/2009)Spanish researchers have measured CO2 levels for the past three years in the troposphere (lower atmosphere) over a sparsely inhabited rural area near Valladolid. The results, which are the first of th
(Date:12/3/2009)The 30-year record low in Antarctic snowmelt that occurred during the 2008-09 austral summer was likely due to concurrent strong positive phases for two main climate drivers, ENSO (El Nio - Southern O
(Date:12/2/2009)PHILADELPHIA New study results strengthen the evidence that people who smoke cigarettes over a long period of time have an increased risk for developing colorectal cancer, even after adjusting for ot
Breaking Biology News(10 mins):CO2 levels rising in troposphere over rural areas 2CCNY professor foresees rising Antarctic snowmelt 2Cigarette smoking increases colorectal cancer risk 2Ten Professional Societies Join Forces to Develop Obesity Medicine Certification Examination 53683 1Ten Professional Societies Join Forces to Develop Obesity Medicine Certification Examination 53683 2Neuropathic pain 3A The sea provides a new hope of relief 9475 1Neuropathic pain 3A The sea provides a new hope of relief 9475 2Demi Lovato Joins National Bullying Prevention Movement 53681 1Demi Lovato Joins National Bullying Prevention Movement 53681 2
...maceuticals, Inc. today announced that it has been...vation Research Grant (SBIR) from the National Ins... Institutes of Health (NIH) to develop in vivo zeb...rome (CYP) P450s. CYP profiling, a critical step ...rug Administration (FDA) for all new drug approval...
...the University of Florida, has donated $250,000 to...e establishment of an endowment to award creative ... find alternative solutions to problems that signi...t from the $250,000 will be presented to the winne...Innovation and Creativity in Entomology. , "I wan...
...is. Pop culture heedlessly and wrongly lumps th... paleontologists assumed that because the creature...sing only two legs to take flight. , Now comes...aunching some 500 pounds of reptilian heft into fl...re ultra-strong wings which, when folded and balan...
Other Biology News:NIH grants Phylonix Phase II SBIR to develop high-throughput in vivo zebrafish assays 2Florida professor creates endowment for insect scientists 2Four, three, two, one . . . pterosaurs have lift off 2
Mouse Anti-hnRNP F / H Monoclonal Antibody, Unconjugated, Clone 1G11 from Novus Biologicals
Rabbit Anti-Human Reptin / TIP49B / RUVB2 Polyclonal Antibody, Unconjugated from Abcam
Anti-Jak3 Antibody, Unconjugated from Cell Signaling Technology
Mouse Anti-Human XPC Polyclonal Antibody, Unconjugated from ABR-Affinity BioReagents
Biology Products: